Introduction {#cncr31921-sec-0005}
============

The phosphatidylinositol 3‐kinase (PI3K) pathway is frequently deregulated in human cancers, and the catalytic PI3K subunit P110 is the mediator of the effects of many deregulated extracellular tyrosine kinase receptors. Moreover, other major nodes of this pathway, including AKT serine/threonine kinase (AKT) and mammalian target of rapamycin (mTOR), can be activated though constitutive or redundant intracellular processes.[1](#cncr31921-bib-0001){ref-type="ref"} Negative regulators of the PI3K pathway, such as phosphatase and tensin homolog (PTEN), also have been well characterized. This important cancer pathway is involved in important fluctuating processes that promote malignant growth and resistance.[2](#cncr31921-bib-0002){ref-type="ref"}, [3](#cncr31921-bib-0003){ref-type="ref"}

Altered PI3K signaling may be caused by several types of genomic alterations, including mutation, amplification, and methylation.[4](#cncr31921-bib-0004){ref-type="ref"} Indeed, across various solid tumor types sampled from patients with cancer in a hot‐spot analysis of known regions of PI3K pathway genes, at least 1 PI3K pathway alteration was described in 38%.[5](#cncr31921-bib-0005){ref-type="ref"} Malignancies frequently associated with PI3K alterations include endometrial, breast, lung, and prostate cancers,[6](#cncr31921-bib-0006){ref-type="ref"}, [7](#cncr31921-bib-0007){ref-type="ref"}, [8](#cncr31921-bib-0008){ref-type="ref"} but almost any tumor type can harbor PI3K genomic alterations in a subset of patients.[5](#cncr31921-bib-0005){ref-type="ref"} Because of the importance of this pathway for human cancers, numerous small molecules targeted to inhibit different steps of its activation have entered clinical development.[4](#cncr31921-bib-0004){ref-type="ref"}, [6](#cncr31921-bib-0006){ref-type="ref"}

However, despite extensive drug‐development efforts over many years, few PI3K pathway inhibitors actually have been approved. Approvals were obtained for everolimus, temsirolimus (both of which are mTOR inhibitors), and idelalisib (which blocks the p110‐δ subunit of the PI3K enzyme). Recently, copanlisib, a potent PI3K‐α and PI3K‐δ inhibitor (but with significant inhibitory activity against PI3K‐β and PI3K‐γ) was approved for lymphomas.[9](#cncr31921-bib-0009){ref-type="ref"} However, many other drugs failed to demonstrate clinical efficacy.[10](#cncr31921-bib-0010){ref-type="ref"}, [11](#cncr31921-bib-0011){ref-type="ref"} Overall, PI3K inhibitors are characterized by low activity as monotherapies, an absence of well characterized genomic predictive markers, and redundant mechanisms of resistance.[12](#cncr31921-bib-0012){ref-type="ref"}, [13](#cncr31921-bib-0013){ref-type="ref"}

Recently, targeted therapies developed under a biomarker‐driven rationale have exhibited greater efficacy and a more successful development pathway compared with agents that were developed for unselected patients with cancer.[14](#cncr31921-bib-0014){ref-type="ref"}, [15](#cncr31921-bib-0015){ref-type="ref"}, [16](#cncr31921-bib-0016){ref-type="ref"}, [17](#cncr31921-bib-0017){ref-type="ref"} However, biomarker‐driven studies are not always successful.[18](#cncr31921-bib-0018){ref-type="ref"} The reasons why this type of development has been less successful for PI3K‐directed agents are not clear but could be related to the molecules themselves or to co‐existing resistance pathways. Indeed, it is well known that mitogen‐activated protein kinase kinase (MEK) pathway alterations are more common in patients with PI3K signaling anomalies than in those without such anomalies and that MEK anomalies can mediate resistance.[19](#cncr31921-bib-0019){ref-type="ref"}, [20](#cncr31921-bib-0020){ref-type="ref"} An in‐depth characterization of the PI3K genomic landscape, along with a description of concomitant genetic alterations that could lead to resistance to pathway inhibition, is urgently needed. Herein, we characterize the PI3K‐related genomic portfolios of 60,991 patients, including rare disease and histology types not previously well assessed, who underwent clinical‐grade next‐generation sequencing.

Materials and Methods {#cncr31921-sec-0006}
=====================

Tissue Sampling {#cncr31921-sec-0007}
---------------

Consecutive samples submitted by thousands of physicians world‐wide were analyzed using a commercial Clinical Laboratory Improvement Amendment‐certified laboratory (Foundation Medicine, Inc, Cambridge, MA; available at: [https://www.foundationmedicine.com](://www.foundationmedicine.com)). Indications for genomic testing were at the discretion of the ordering physicians. Tissue diagnoses were designated according to the pathology report described by the ordering physicians and further verified by a pathologist at Foundation Medicine. DNA was extracted from formalin‐fixed, paraffin‐embedded tissue, as previously described.[21](#cncr31921-bib-0021){ref-type="ref"} Patient identification was anonymized for the study. Approval for the Foundation Medicine cohort, including a waiver of informed consent and a Health Insurance Portability and Accountability Act of 1996 waiver of authorization, was obtained from the Western Institutional Review Board (protocol no. 20152817).

Next‐Generation Sequencing {#cncr31921-sec-0008}
--------------------------

DNA was extracted from formalin‐fixed, paraffin‐embedded sections, and comprehensive genomic profiling was performed on hybridization‐captured, adaptor ligation‐based libraries to a median depth of coverage of \>500X.[21](#cncr31921-bib-0021){ref-type="ref"} The platform simultaneously sequenced the coding regions of 315 cancer‐related genes plus introns from 28 genes that often are rearranged or altered in cancer. Alterations captured by next‐generation sequencing included base‐pair substitutions, insertions/deletions (both short and long), copy‐number alterations, and rearrangements.

Clustering of Genetic Alterations and Tumor Types {#cncr31921-sec-0009}
-------------------------------------------------

Genomic alterations were classified as activators of the PI3K pathway (18 genes) or mediators of PI3K resistance (Supporting Table [1](#cncr31921-sup-0001){ref-type="supplementary-material"}). An analysis of frequencies was performed according to disease ontologies (clustered according to the American Joint Committee on Cancer's *AJCC Cancer Staging Handbook*, seventh edition)[22](#cncr31921-bib-0022){ref-type="ref"} and also according to tumor histologies (according to the ordering physician's pathology report).

Statistical Analysis {#cncr31921-sec-0010}
--------------------

Statistical analysis was performed using GraphPad Prism (GraphPad Software, La Jolla, CA), Python 2.7 (Python Software Foundation, Beaverton, OR), and Anaconda (version 4‐4.3.21; Anaconda Inc, Austin, TX). A co‐occurrence analysis was performing matching genomic alterations in the PI3K pathway with 3 different subsets of genomic alterations (the mitogen‐activated kinase \[MAPK\] pathway, the tumor protein 53 \[*TP53*\] pathway, and the estrogen receptor 1 \[*ESR1*\] and/or androgen receptor \[*AR*\] \[hormone receptor\] pathway).

Results {#cncr31921-sec-0011}
=======

Alterations in any gene of the PI3K pathway were identified in 44% of the 60,991 tumors analyzed (Fig. [1](#cncr31921-fig-0001){ref-type="fig"}). The most frequently altered gene was PIK3 catalytic subunit α (*PIK3CA*) (13.3%), followed by *PTEN* (9.4%), serine/threonine kinase 11 (*STK11*) (4.8%), and F‐box and WD repeat domain containing 7 (*FBXW7*) (3.4%) (Fig. [1](#cncr31921-fig-0001){ref-type="fig"}C,F). Alterations in some genes were rare in our population, including regulatory‐associated protein of mTOR/independent companion of mTOR complex 2 (*RICTOR*) (0.02%), PIK3 regulatory subunit 2 (*PIK3R2*) (0.36%), and inositol polyphosphatate‐4‐phosphatase type IIB *(INPP4B)* (0.43%). Important variations in the frequency of PI3K alterations were detected according to histology and tumor type.

![Genetic alterations in the phosphoinositide 3‐kinase (PI3K) pathway are illustrated in patients with cancer. The percentages of patients who had alterations are indicated on the y‐axis. The analysis of alteration frequency (%) was calculated based on at least 1 alteration per patient. Numbers in parentheses indicate the numbers of patients. (A) Results from an analysis of overall alterations are illustrated according to histology. **"**All" represents all samples, regardless of histology. GIST indicates gastrointestinal stromal tumor. (B) Specific gene alteration frequencies are illustrated according to histology. (C) The percentages of gene alterations are illustrated according to histology corresponding to A and B. The far right column lists the number of genes that were altered for each associated histologic type, and the bottom row indicates the number of histologies (from a total of 16) that had alterations in the listed genes (columns). (D) Results from an analysis of the overall percentages of alterations are illustrated according to disease type. Carc. indicates carcinoma; GEJ, gastroesophageal junction; NSCLC, nonsmall cell lung cancer; SCLC, small cell lung cancer. (E) Percentages of specific gene alterations are illustrated according to disease type. Other types include parathyroid carcinoma, placenta choriocarcinoma, spine ependymoma, soft tissue paraganglioma, spine glioma, and eye lacrimal duct carcinoma. (F) The percentages of gene alterations are illustrated according to disease type corresponding to D and E. The far right column lists the number of genes that were altered in for each associated disease type, and the bottom row indicates the number of disease types (from a total of 34) that had alterations in the listed genes (columns). On charts C and F, pink shading denotes the percentage above the median, yellow shading denotes the percentage below the median; 0% without shading indicates values of 0%, and 0% with shading indicates values between 0.001% and 0.5%. *AKT1* indicates AKT serine/threonine kinase 1; *AKT2*, AKT serine/threonine kinase 2; *AKT3*, AKT serine/threonine kinase 3; *FBXW7*, F‐box and WD repeat domain containing 7; *INPP4B*, inositol polyphosphatate‐4‐phosphatase type IIB; *MTOR*, mammalian target of rapamycin; *PIK3C2B*, PIK3 catalytic subunit 2β; *PIK3CA*, PIK3 catalytic subunit α; *PIK3CB*, PIK3 catalytic subunit β; *PIK3CG*, PIK3 catalytic subunit γ; *PIK3R1*, PIK3 regulatory subunit 1; *PIK3R2*, PIK3 regulatory subunit 2; *PTEN*, phosphatase and tensin homolog; *RICTOR*, regulatory‐associated protein of mTOR/independent companion of mTOR complex 2; *RPTOR*, regulatory‐associated protein of mTOR complex 1; *STK11*, serine/threonine kinase 11; *TSC1*, tuberous sclerosis complex subunit 1; *TSC2*, tuberous sclerosis complex subunit 2.](CNCR-125-1185-g001){#cncr31921-fig-0001}

Analysis by Histology {#cncr31921-sec-0012}
---------------------

The distribution of alterations of 18 genes in the PI3K pathway was analyzed according to histology. Sixteen histologies were evaluated, and all had at least 1 PI3K pathway alteration (Fig. [1](#cncr31921-fig-0001){ref-type="fig"}A‐C). There was significant variation in the patterns of PI3K alterations between histologies. Carcinosarcomas (89% had PI3K pathway alterations) and squamous cell carcinomas (62% had PI3K pathway alterations) were the most altered histologies, whereas sarcomas (16% had PI3K pathway alterations), mesotheliomas (14% had PI3K pathway alterations), and gastrointestinal stromal tumors (GISTs) (11% had PI3K pathway alterations) were the least common.

*PIK3CA* was the most frequently altered gene across the 16 histologies (13% overall) and was altered in every histology evaluated (Fig. [1](#cncr31921-fig-0001){ref-type="fig"}B). Carcinosarcomas had the highest incidence of *PIK3CA* alteration (28% had *PIK3CA* alterations), followed by squamous cell carcinomas (23% had *PIK3CA* alterations), urothelial carcinomas (19% had *PIK3CA* alterations), adenocarcinomas (15% had *PIK3CA* alterations), and adenosquamous carcinomas (14% had *PIK3CA* alterations). Although *PIK3CA* was altered most frequently across histologies, at a 1.4 times higher rate than *PTEN* (13% vs 9% had *PIK3CA* alterations), a subset of histologies had significantly higher rates (*P* \< .0001) of *PTEN* alterations than *PIK3CA* alterations: these included gliomas (29% vs 12%), melanomas (12% vs 3%), neuroendocrine tumors (10% vs 5%), and GISTs (5% vs 0%). Although the difference was not significant, *PTEN* also was altered at a higher rate than *PIK3CA* in undifferentiated carcinomas (21% vs 11%; *P* = .0755).

Other alteration rates to note by histology included *RICTOR*, which was altered at a very low rate overall (0.02% of patients) but was altered in all histologies except adenoid cystic. Urothelial cancers had a significantly higher rate of tuberous sclerosis complex subunit 1 (*TSC1*) alterations than all other histologies (8% vs 0%‐2%), whereas carcinosarcomas had a significantly higher rate of AKT serine/threonine kinase 2 (*AKT2*) alterations than other histologies (12% vs 1%‐3%). *STK11* was altered at a 5% rate across histologies but was aberrant in 14% and 16% of patients with adenosquamous and large‐cell carcinomas, respectively. Although *PIK3R2* and regulatory‐associated protein of mTOR complex 1 (*RPTOR*) were altered at a slightly higher rate than *RICTOR* (0.36% and 0.44%, respectively), they were the least frequently altered genes according to histology and were altered in 11 of the 16 histologies at a rate of 1% or less.

Analysis by Disease Type {#cncr31921-sec-0013}
------------------------

Six of the 34 disease types had higher rates of PI3K pathway alterations than the overall average of 44%, including 4 of 5 "female" cancers (ie, cancers of the uterus \[77% of patients had an alteration\], cervix \[62%\], breast \[58%\], and vagina/vulva \[46%\]) (Fig. [1](#cncr31921-fig-0001){ref-type="fig"}D‐F). The exception was ovarian cancers, which were altered in 30% of patients. Lung cancers, including large cell carcinomas and nonsmall cell lung cancers (NSCLCs), had alterations in 39% and 38% of patients, respectively; whereas small cell lung cancers were altered in 30% of patients. Soft tissue sarcomas and adrenal gland cancers were the least frequently altered (in 11% of patients), whereas testis cancers had the lowest number of altered PI3K pathway genes (only 6 of 18 genes) (Fig. [1](#cncr31921-fig-0001){ref-type="fig"}E).

*PIK3CA* was altered most frequently across disease types (13% of patients had an alteration) and was the only gene altered in every disease type. *PTEN* was altered in 9% of patients and in all but 1 disease type (adrenal gland). Notably, in addition to the female cancers listed above, anus cancer also had a higher than average number of alterations in both *PIK3CA* and *PTEN*. Similar to histologic differences, several cancers had significantly higher rates (*P* \< .0001) of *PTEN* alterations than *PIK3CA* alterations, including melanoma (12%), brain cancer (25%), prostate cancer (34%), and bone cancer (10%; *P* = .03). *STK11* was altered at a significantly higher rate in cervical cancer, lung large cell carcinoma, and NSCLC, whereas altered *FBXW7* was notably more frequent in corpus uteri cancer, anal cancer, colorectal cancer, and melanoma. *TSC2* was altered in 5% of liver cancers, compared with 1% overall. Bladder (7%) and kidney (4%) cancers had significant more mutations in *TSC1* compared with other disease types (1%).

### Uterine cancers {#cncr31921-sec-0014}

Because uterine cancers had the highest overall rate of PI3K pathway alterations (77% of patients with uterine cancer had alterations vs 62% of those with cervical cancer; *P* \< .0001) and had a significantly higher percentage of *PIK3R1* alterations than the next highest disease type (20%; *P* \< .0001), we performed an additional, detailed analysis of the top PI3K pathway genes that were altered in this disease (see Fig. [1](#cncr31921-fig-0001){ref-type="fig"}E,F). *PIK3CA* was altered in 40% of patients, followed closely by *PTEN*. In 2% of patients, *PIK3R1* was the only PI3K gene altered, whereas *PIK3CA* was the only PI3K gene altered in 10% of the uterine cancer cohort (with an overall uterine cohort alteration rate of 40%).

### Rare cancers {#cncr31921-sec-0015}

Rare cancers for which, to our knowledge, comprehensive genomic profiles have not been previously published by The Cancer Genome Atlas (TCGA) (although some have been reported outside of TCGA),[23](#cncr31921-bib-0023){ref-type="ref"}, [24](#cncr31921-bib-0024){ref-type="ref"}, [25](#cncr31921-bib-0025){ref-type="ref"}, [26](#cncr31921-bib-0026){ref-type="ref"} include adenoid cystic, anus, neuroendocrine, nonmelanoma skin, salivary gland, small intestine, thyroid, vaginal and vulvar, and unknown primaries (Fig. [2](#cncr31921-fig-0002){ref-type="fig"}A‐I). Unknown primaries differ in their genomic alterations, as might be suspected, based on the histologic differences described above. Thyroid cancers are primarily altered in *PIK3CA* and *PTEN*, including a higher proportion of *PIK3CA* alterations in the anaplastic subtype (12%) compared with well differentiated thyroid cancers (5%). Higher proportions of genomic alterations in *FBXW7*, *MTOR*, *PIK3CA*, and *STK11* were detected in vulvar cancers compared with vaginal cancers. Adenoid cystic cancers had very few alterations in the PI3K pathway, but *PIK3R1* alterations (6%) were detected more frequently compared with other cancers in general (2%). In anal cancers, higher frequencies of alterations were detected in *FBXW7*, *PIK3CA*, and *PTEN*, which were observed almost exclusively in tumors that had squamous histology compared with basaloid carcinomas. Neuroendocrine cancers had low rates of *PIK3CA* alterations compared with other cancers (\<10%). It is important to note the high frequency of *PTEN* alterations in prostate small cell carcinomas (35%), similar to prostate cancers overall (34%).

![Phosphoinositide 3‐kinase (PI3K) pathway alterations are illustrated in rare or uncommon cancer types. The percentages of patients who had alterations are indicated. Numbers in parentheses represent the numbers of patients. The cancer types illustrated include: (A) unknown primaries, (B) thyroid, (C) adenoid cystic, (D) salivary gland, (E) skin (nonmelanoma), (F) vaginal and vulvar, (G) anus, (H) neuroendocrine tumors, and (I) small intestine. *AKT1* indicates AKT serine/threonine kinase 1; *AKT2*, AKT serine/threonine kinase 2; *AKT3*, AKT serine/threonine kinase 3; *FBXW7*, F‐box and WD repeat domain containing 7; *INPP4B*, inositol polyphosphatate‐4‐phosphatase type IIB; *MTOR*, mammalian target of rapamycin; NOS, not otherwise specified; *PIK3C2B*, PIK3 catalytic subunit 2β; *PIK3CA*, PIK3 catalytic subunit α; *PIK3CB*, PIK3 catalytic subunit β; *PIK3CG*, PIK3 catalytic subunit γ; *PIK3R1*, PIK3 regulatory subunit 1; *PIK3R2*, PIK3 regulatory subunit 2; *PTEN*, phosphatase and tensin homolog; *RICTOR*, regulatory‐associated protein of mTOR/independent companion of mTOR complex 2; *RPTOR*, regulatory‐associated protein of mTOR complex 1; *STK11*, serine/threonine kinase 11; *TSC1*, tuberous sclerosis complex subunit 1; *TSC2*, tuberous sclerosis complex subunit 2.](CNCR-125-1185-g002){#cncr31921-fig-0002}

Co‐Occurrence of PI3K Alterations and MAPK, TP53, and Hormone Receptor Pathway Alterations {#cncr31921-sec-0016}
------------------------------------------------------------------------------------------

The likelihood of a co‐occurrence of an alteration in the PI3K pathway, in either the MAPK pathway or the hormone receptor pathway, or in *TP53* was analyzed by disease type. Some tumors revealed a higher likelihood of a co‐occurrence of alterations in both pathways compared with an isolated alteration, especially for colorectal cancers (odds ratio \[OR\], 1.64; *P* \< .001), mesotheliomas (OR, 2.67; *P* = .024), anal cancers (OR, 1.98; *P* = .03), and nonsquamous head and neck cancers (OR, 2.03; *P* = .019) (Fig. [3](#cncr31921-fig-0003){ref-type="fig"}A, Table [1](#cncr31921-tbl-0001){ref-type="table"}). In contrast, for liver cholangiocarcinomas, endometrial endometrioid tumors, lung and unknown primary squamous cell carcinomas, lobular breast carcinomas, and glioblastomas, alterations in the PI3K or MAPK pathway most likely occurred as isolated events.

![Charts illustrate the co‐occurrence of pathway alterations in the phosphoinositide 3‐kinase (PI3K) pathway and the (A) mitogen‐activated kinase (*MAPK*) pathway, (B) tumor protein 53 (*TP53*), and (C) estrogen receptor 1 (*ESR1*) and/or androgen receptor (*AR*) (hormone receptor) pathways. (A) The co‐occurrence of alterations in the *MAPK* pathway and the PI3K pathway is illustrated. The ratio of alterations in the PI3K pathway only, in the MAPK pathway only, and in both pathways is depicted for all disease types, and a significant association is noted between the 2 pathways (*P* ≤ .05 for co‐occurrence; in total, 14 disease types had a significant association). (B) The co‐occurrence of pathway alterations in the *TP53* pathway and the PI3K pathway is illustrated. The ratio of alterations in the PI3K pathway only, in the *TP53* pathway only, and in both pathways is depicted for all disease types, and a significant association is noted between the 2 pathways (*P* ≤ .05 for co‐occurrence; in total, 21 disease types had a significant association). (C) The co‐occurrence of alterations in the hormone receptor pathways and the PI3K pathway is illustrated. The ratio of alterations in the PI3K pathway only, in the *ESR1* and/or *AR* pathway only, or in both pathways is depicted for all disease types, and a significant association is noted between the 2 pathways (*P* ≤ .05 for co‐occurrence; in total, 33 disease types had a significant association). No alterations in either *ESR1* or *AR* were observed in kidney clear cell carcinoma, cervix adenocarcinoma, bladder urothelial (transitional cell) carcinoma, small intestine adenocarcinoma, breast metaplastic carcinoma, kidney urothelial carcinoma, duodenum adenocarcinoma, cervix squamous cell carcinoma (SCC), lung large cell neuroendocrine carcinoma, salivary gland carcinoma (not otherwise specified \[NOS\]), head and neck adenoid cystic carcinoma, unknown primary undifferentiated small cell carcinoma, ovary carcinosarcoma, uterus endometrial adenocarcinoma (NOS), uterus endometrial adenocarcinoma endometrioid, thymus carcinoma (NOS), brain ependymoma, or diffuse type stomach adenocarcinoma. CNS indicates central nervous system; CRC, colorectal cancer; GIST, gastrointestinal stromal tumor; HCC, hepatocellular carcinoma; HNSCC, head and neck squamous cell carcinoma; NSCLC, nonsmall cell lung cancer; SCLC, small cell lung cancer.](CNCR-125-1185-g003){#cncr31921-fig-0003}

###### 

Co‐Occurrence of Alterations Between the Phosphatidylinositol 3‐Kinase Pathway and the Mitogen‐Activated Kinase Pathway[a](#cncr31921-note-0003){ref-type="fn"}

  Disease Type                 PI3K Pathway Exclusive Alteration   MAPK Pathway Exclusive Alteration   Double Mutant   Neither Alteration   OR for Altered PI3K in MAPK Mutant vs Wild Type   OR for MAPK Mutant in PI3K Altered vs Wild Type   *P*
  ---------------------------- ----------------------------------- ----------------------------------- --------------- -------------------- ------------------------------------------------- ------------------------------------------------- -------
  All tumors                   16,004                              17,574                              9932            26,450               0.96                                              0.96                                              .0001
  Anal                         107                                 1                                   9               93                   1.68                                              7.29                                              .0252
  Biliary                      333                                 924                                 261             964                  0.86                                              0.90                                              .0341
  Cervix                       233                                 61                                  56              129                  0.74                                              0.60                                              .0022
  CRC                          665                                 3050                                2351            1842                 1.64                                              1.25                                              .0001
  Gastrointestinal NET         169                                 160                                 59              666                  1.33                                              1.34                                              .0343
  Gliomas, high grade          1294                                115                                 130             825                  0.87                                              0.75                                              .0159
  Gliomas, low grade           329                                 171                                 34              887                  0.61                                              0.58                                              .0013
  Head and neck, nonsquamous   41                                  15                                  13              138                  2.03                                              2.46                                              .0185
  Melanoma                     160                                 965                                 431             444                  1.17                                              1.06                                              .0485
  Mesothelioma                 46                                  13                                  6               343                  2.67                                              3.16                                              .0235
  NSCLC, adenocarcinoma        1587                                3633                                2060            3281                 1.11                                              1.07                                              .0001
  NSCLC, squamous              865                                 191                                 160             718                  0.83                                              0.74                                              .0025
  Pancreas                     61                                  2170                                353             240                  0.69                                              0.95                                              .0056
  Salivary gland               80                                  72                                  55              185                  1.43                                              1.45                                              .0125
  SCLC                         276                                 61                                  44              617                  1.36                                              1.53                                              .0268

Abbreviations: CRC: colorectal carcinoma; MAPK, mitogen‐activated kinase; NET: neuroendocrine tumor; NSCLC: nonsmall cell lung cancer; OR, odds ratio; PI3K, phosphatidylinositol 3‐kinase; SCLC: small cell lung cancer.

Only tumors with a statistically significant association are included in this table.

John Wiley & Sons, Ltd

When all tumors were analyzed, there were no significant co‐occurrences between PI3K and TP53 pathway alterations (Fig. [3](#cncr31921-fig-0003){ref-type="fig"}B, Table [2](#cncr31921-tbl-0002){ref-type="table"}). Nonetheless, among other tumor types, positive co‐occurrences were detected for some gastrointestinal tumors, including colorectal cancer (OR, 1.55; *P* \< .001), hepatocellular carcinoma (OR, 2.32; *P* \< .001), and gastric cancer (OR, 2.87; *P* = .006).

###### 

Co‐Occurrence of Alterations Between the Phosphatidylinositol 3‐Kinase Pathway and Tumor Protein 53[a](#cncr31921-note-0005){ref-type="fn"}

  Disease Type           PI3K Pathway Exclusive Alteration   *TP53* Alteration   Double Mutant   Neither Alteration   OR for Altered PI3K in *TP53* Mutant vs Wild Type   OR for Mutant *TP53* in PI3K Altered vs Wild Type   *P*
  ---------------------- ----------------------------------- ------------------- --------------- -------------------- --------------------------------------------------- --------------------------------------------------- ---------
  All tumors             11,227                              24,670              14,709          19,354               1.02                                                1.01                                                .0835
  Adrenal gland          23                                  72                  3               150                  0.30                                                0.33                                                .0399
  Colorectal             1076                                4024                1940            868                  1.55                                                1.66                                                .0001
  Corpus uteri           644                                 329                 679             115                  0.59                                                0.78                                                .0001
  Gastrointestinal NET   96                                  262                 132             564                  0.98                                                1.00                                                .0001
  Gliomas, low grade     234                                 444                 129             614                  1.82                                                2.02                                                .035
  HCC                    63                                  131                 58              298                  2.32                                                2.50                                                .0005
  HNSCC                  176                                 412                 197             234                  0.94                                                0.92                                                .0007
  Kidney                 234                                 116                 76              842                  0.75                                                0.83                                                .0001
  Mesothelioma           35                                  56                  17              300                  0.91                                                0.91                                                .0058
  NSCLC, other           253                                 1121                725             564                  0.99                                                0.99                                                .0001
  NSCLC, squamous        114                                 751                 911             158                  1.27                                                1.11                                                \< .001
  Prostate               360                                 342                 385             543                  0.43                                                0.54                                                .0001
  Salivary gland         60                                  93                  75              164                  1.33                                                1.34                                                .0003
  SCLC                   21                                  583                 299             95                   1.67                                                1.54                                                .0005
  Skin (nonmelanoma)     37                                  227                 130             134                  1.87                                                1.09                                                .0007
  Soft tissue sarcoma    35                                  66                  20              397                  1.10                                                1.07                                                .0002
  Stomach                206                                 1201                442             421                  2.87                                                2.55                                                .0058
  Testis                 10                                  13                  7               70                   0.82                                                0.92                                                .0397
  Thyroid                72                                  117                 58              437                  1.89                                                1.69                                                .0001
  Unknown primary        673                                 1730                972             1391                 2.34                                                2.11                                                .0165
  Vagina and vulva       37                                  38                  17              25                   1.10                                                1.07                                                .0027

Abbreviations: HCC, hepatocellular carcinoma; HNSCC, head and neck squamous cell carcinoma; NET, neuroendocrine tumor; OR, odds ratio; PI3K, phosphatidylinositol 3‐kinase; SCC, squamous cell carcinoma; SCLC, small cell lung cancer; *TP53*, tumor protein 53.

Only tumors with a statistically significant association are included in this table.

John Wiley & Sons, Ltd

A significant co‐occurrence ratio was present between PI3K pathway alterations and hormone receptor alterations in *ESR1* and *AR* (OR, 1.53; *P* \< .01) (Fig. [3](#cncr31921-fig-0003){ref-type="fig"}C, Table [3](#cncr31921-tbl-0003){ref-type="table"}). However, this positive correlation was restricted to a few tumor types (bladder, colorectal, corpus uteri, prostate, and unknown primary cancers).

###### 

Co‐Occurrence of Alterations Between the Phosphatidylinositol 3‐Kinase Pathway and Estrogen Receptor 1/Androgen Receptor[a](#cncr31921-note-0007){ref-type="fn"}

  Disease Type                   PI3K Pathway Exclusive Alteration   *ESR1*/*AR* Alteration   Double Mutant   Neither Alteration   OR for Altered PI3K in *ESR1*/*AR* Mutant vs Wild Type   OR for Mutant *ESR1*/*AR* in PI3K Altered vs Wild Type   *P*
  ------------------------------ ----------------------------------- ------------------------ --------------- -------------------- -------------------------------------------------------- -------------------------------------------------------- -------
  All tumors                     25,025                              718                      911             43,306               1.53                                                     2.15                                                     .0001
  Bladder and urothelial tract   680                                 0                        6               998                  2.47                                                     ---[b](#cncr31921-note-0008){ref-type="fn"}              .0045
  Colorectal                     2984                                23                       32              4869                 1.53                                                     2.26                                                     .0031
  Corpus uteri                   1272                                3                        51              441                  1.27                                                     5.71                                                     .0003
  Prostate                       523                                 183                      222             702                  1.28                                                     1.44                                                     .0001
  Unknown primary                1627                                16                       18              3105                 1.54                                                     2.13                                                     .0292

Abbreviations: *AR*, androgen receptor; *ESR1*, estrogen receptor 1; OR, odds ratio; PI3K, phosphatidylinositol 3‐kinase pathway; SCLC: small cell lung cancer.

Only tumors with a statistically significant association are included in this table.

Because there were no *ESR1*/*AR* alterations, a value could not be computed.

John Wiley & Sons, Ltd

Types of Genetic Alterations {#cncr31921-sec-0017}
----------------------------

Different types of alterations were identified in the 18 PI3K pathway genes (Supporting Table [2](#cncr31921-sup-0001){ref-type="supplementary-material"}). Only alterations that were considered pathogenic or likely pathogenic were reported. Single nucleotide changes were the predominant genetic alterations in 15 of the18 genes (83%), whereas copy number changes were predominant in *AKT2* (1.6%), *AKT3* (0.9%), and PIK3 catalytic subunit 2β (*PIK3C2B*) (1.2%). Although copy number changes and rearrangements were identified infrequently (11% and 0.9%, respectively), they still represent approximately 7300 patients for whom these alterations might inform potential treatments. Of the single nucleotide changes reported, 63% were missense, 29% were nonsense, and 8% were splice variants (Supporting Fig. [1](#cncr31921-sup-0001){ref-type="supplementary-material"}).

Discussion {#cncr31921-sec-0018}
==========

PI3K pathway alterations are observed frequently in diverse solid tumors, making this pathway an attractive target for cancer therapies. Historically, monotherapy against this pathway has had mixed efficacy. An analysis of specific alterations in the key genes of the pathway and of the co‐occurrence of complementary, activated resistance signals may inform nuanced treatment options and combination strategies that were not previously considered. To our knowledge, this is the largest analysis to date in terms of both the total number of patients evaluated (n = 60,991) and the number of PI3K pathway genes interrogated (18 genes), and it includes data for multiple, rare cancers that were not previously selected by TCGA.

Overall, we report that at least1 PI3K pathway alteration occurred in 44% of tumors. For comparison, our previous analysis included 19,784 solid tumors and reported ≥1 alteration in 38% of patients.[5](#cncr31921-bib-0005){ref-type="ref"} In that previous study, alterations were restricted to *PIK3CA*, *PTEN*, and *AKT1* but also included an analysis of *PTEN* loss by immunohistochemistry (not reported here), which was present in 30% of samples. Several other studies were cataloged by the cBioPortal,[27](#cncr31921-bib-0027){ref-type="ref"}, [28](#cncr31921-bib-0028){ref-type="ref"} including an extensive analysis by TCGA and the Memorial Sloan Kettering Impact project.[29](#cncr31921-bib-0029){ref-type="ref"} This combined analysis included approximately 33,000 patients with various types of solid tumors and indicated that 37% had alterations in ≥1 of the analyzed PI3K pathway genes.

We also focused on reporting PI3K pathway alterations in rare tumor types, for which few or no studies are available.[23](#cncr31921-bib-0023){ref-type="ref"}, [24](#cncr31921-bib-0024){ref-type="ref"}, [25](#cncr31921-bib-0025){ref-type="ref"}, [26](#cncr31921-bib-0026){ref-type="ref"} Overall, *PIK3CA* continues to be the most frequently altered gene, predominantly in squamous cell histologies, including anal (32%), vulvar (23%), and unknown primary (22%) sites. Neuroendocrine carcinomas in general were silent for PI3K alterations. Relevant exceptions occurred, 12% of tumors at colon neuroendocrine sites had alterations in *FBXW7*, and 35% of tumors at prostate neuroendocrine sites had *PTEN* mutations, mirroring the general tumor site frequency rather than the histology itself.[30](#cncr31921-bib-0030){ref-type="ref"}

Carcinosarcoma was the histologic type with the most frequent number of PI3K pathway alterations (89%). We included 297 samples (predominantly uterine \[n = 178\] and ovarian \[n = 99\] in origin), which represent the largest series of molecular‐profiled carcinosarcomas to date. These tumors are rare and usually have a worse prognosis compared with carcinomas of the same anatomic site, and scarce therapeutic options are available.[31](#cncr31921-bib-0031){ref-type="ref"} The cBioPortal catalog included 78 patients with uterine carcinosarcomas and reported PI3K pathway alterations in 71% of samples.[27](#cncr31921-bib-0027){ref-type="ref"} Here, we describe a lower frequency of alterations in individual genes compared with previous small series that reported mutations in *PIK3CA* (41%), *PTEN* (41%), and *PIK3R1* (14%).[32](#cncr31921-bib-0032){ref-type="ref"} A significantly greater number of samples and a higher proportion of carcinosarcomas of ovarian origin in our series may explain these differences. It is interesting to note our data suggesting that the PI3K landscape of alterations is more similar to that of uterine carcinomas than general sarcomas, reinforcing the biologic relatedness of both.[31](#cncr31921-bib-0031){ref-type="ref"} An important difference was the greater number of AKT2 alterations in carcinosarcomas (12% vs 3% in uterine cancers in general vs 2% in solid tumors). AKT2 has been implicated in the epithelial‐to‐mesenchymal transition,[33](#cncr31921-bib-0033){ref-type="ref"} for which carcinosarcomas represent 1 of the best examples in human cancers.

Several reviews have provided a good background describing the difficulties in developing efficacious PI3K pathway inhibitors as well as the paucity of successful clinical trials that resulted in drug approval targeted to specific alterations in this pathway.[4](#cncr31921-bib-0004){ref-type="ref"}, [34](#cncr31921-bib-0034){ref-type="ref"} Descriptions of novel genomic alterations in the pathway that predict sensitivity to targeted therapies are emerging.[35](#cncr31921-bib-0035){ref-type="ref"} It is important to note that the presence of concomitant alterations in alternative pathways may lead to resistance to PI3K inhibitors.[19](#cncr31921-bib-0019){ref-type="ref"}, [36](#cncr31921-bib-0036){ref-type="ref"} Conversely, the presence of PI3K alterations can cause resistance to other treatments, especially hormone therapies.[37](#cncr31921-bib-0037){ref-type="ref"}, [38](#cncr31921-bib-0038){ref-type="ref"} In the current study, we demonstrated that the co‐occurrence of PI3K pathway alterations and alterations in the *MAPK*, *TP53*, and hormone pathways varied according to tumor types, as expected. A higher co‐occurrence rate of *PI3K* and *MAPK* alterations was observed in some gastrointestinal tumors, including anal and colorectal cancers, which could significantly affect the activity of PI3K pathway inhibitors.[12](#cncr31921-bib-0012){ref-type="ref"} *ESR1* mutations are being implicated as an evolutionary mechanism of acquired resistance to endocrine manipulation, especially in patients with metastatic, previously treated breast cancer.[39](#cncr31921-bib-0039){ref-type="ref"} It is also noteworthy that, for the first time, we report the absence of a significant co‐occurrence of *ESR1* mutations with *PI3K* pathway alterations for breast cancer (OR, 1.01; *P* = .85). Nonetheless, a significant correlation was detected for uterine cancers, suggesting a distinct biologic pathway for the development of resistance between both sites.

*AKT1* is 1 of the PI3K pathway genes activated by mutations, including the most frequent glutamic acid‐to‐lysine (E17K) hotspot mutation.[40](#cncr31921-bib-0040){ref-type="ref"} AKT inhibitor monotherapy has been tested in this setting with initial promising results.[41](#cncr31921-bib-0041){ref-type="ref"} In this study, we reported *AKT1* alterations in 1% of samples. Alterations in *AKT1* are identified more frequently in uterine cancers, breast cancers, and undifferentiated carcinomas. We also analyzed genetic alterations in *STK11*, which recently has been implicated as a resistance mechanism to programmed cell death 1 (PD‐1)/PD‐1 inhibitors.[42](#cncr31921-bib-0042){ref-type="ref"} Although the overall frequency of this alteration was 5%, it is interesting to note that some tumor types had significantly higher frequencies, including NSCLC (14%), large cell lung cancer (12%), and cervical cancer (12%). These results may be important for the future selection of patients for checkpoint inhibitors, especially in these tumor types.

Our current analysis also highlights the need to use a comprehensive genomic profiling approach to identify the full spectrum of alteration types that might be identified in a gene. Hot‐spot panels and other sequencing methods do not interrogate across all 4 classes of genomic alterations (ie, these panels detect single nucleotide variants but do not identify copy numbers, large insertions and deletions, or rearrangements, which occur in an important minority of patients) (Supporting Table [2](#cncr31921-sup-0001){ref-type="supplementary-material"}). Single nucleotide alterations that are not located in common or known regions of the genes also would be missed using hot‐spot technology.

In conclusion, comprehensive genomic profiling of solid tumors has revealed frequent genetic alterations in several genes of the PI3K pathway. Gynecologic, breast, and prostate cancers, along with carcinosarcoma and squamous cell carcinomas of different sites, more frequently harbor PI3K alterations. Our data also suggest that there are different frequencies of alterations and co‐occurrence patterns of resistance pathways according to tumor types, which can directly affect targeted therapeutic opportunities and clinical trial design.
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